Lupin’s North American sales remained weak during the September quarter (Q2), too. Not only did sales decline 32 per cent year-on-year (y-o-y), but were down 15 per cent sequentially, despite five drug launches in the US. In fact, the management commentary after the June quarter (Q1) results indicated only a marginal decline ahead. Analysts say Lupin’s US sales are now lower than before the Gavis acquisition and anti-diabetic Glumetza generics launch. Seasonal weakness in Cephalosporins, Mylans’ launch in Minastrin (iron tablets launched by Lupin in ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Mon, October 30 2017. 23:24 IST
